Seattle Genetics is an attractive short term swing trade. The company currently has an approved product, ADCETRIS® (brentuximab vedotin), and focuses on antibody-drug conjugate technology. Click to read more about my technical analysis and ADC technology.
Arena Pharmaceuticals (NASDAQ: ARNA)
Arena Pharmaceuticals, is a company I see value in. The company’s leading pipeline is etrasimod, in which its worldwide Phase 3 trial for the treatment of moderately to severely active ulcerative colitis is currently in the planning process. Click the title of the post to read more.
Zynerba Pharmaceuticals (NASDAQ: ZYNE)
Zynerba Pharmaceuticals, is a company I see value in. From a technical analysis standpoint, the positive uptrend is an attractive characteristic. Also, with the recent pullback, if ZYNE continues to be supported by the exponential moving average (EMA), it is currently at a “good buy” area. Click the title of the post to read more.
Clinuvel Pharmaceuticals Limited (CLVLY)
Clinuvel is currently carries high volatility, the positive uptrend is appealing for short-term swing trades. Clinuvel is currently near its previous resistance. From a technical analysis, I don’t believe it is currently in the “good buy” territory. However, if Clinuvel continues to make “higher highs and higher lows,” that break the resistance, Clinuvel might offer a substantial profit. Click the title of the post to read more.
Update to Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) – Approved
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO®